Related Experiment Videos
Ischemic heart disease in type 2 diabetes
Irina Otel1, François Ledru, Nicolas Danchin
1Department of Cardiology, Hôpital Européen Georges Pompidou, Paris, France.
Insights
Type 2 diabetes and coronary artery disease (CAD) management requires intensive lifestyle and medication interventions. Specific treatments for diabetic patients with CAD, including glycemic control and revascularization strategies, are crucial for improving outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Diabetology
Background:
- Type 2 diabetes is a growing epidemic, with a significant rise in patients also having coronary artery disease (CAD).
- Diabetic patients with CAD often present with more extensive atherosclerosis, are more frequently asymptomatic with silent myocardial ischemia, and experience poorer outcomes compared to non-diabetics.
- Diagnosing CAD in diabetic patients is challenging due to these specificities.
Purpose of the Study:
- To review the specific challenges and management strategies for coronary artery disease (CAD) in patients with type 2 diabetes.
- To highlight the importance of intensive risk factor intervention and evidence-based secondary prevention medications.
- To discuss the role of glycemic control and revascularization techniques in this patient population.
Main Methods:
- Review of current literature and clinical trial data concerning type 2 diabetes and CAD.
- Analysis of management strategies including lifestyle modifications, pharmacotherapy (antiplatelets, statins, beta-blockers, ACE inhibitors), and glycemic control.
- Evaluation of evidence regarding insulin therapy in acute myocardial infarction and revascularization procedures (angioplasty vs. surgery, role of stents).
Main Results:
- Intensive intervention on lifestyle and risk factors, along with standard secondary prevention medications, is the cornerstone of management.
- Specific glycemic control strategies, particularly using agents targeting K(ATP) channels, show promise.
- Insulin therapy, as suggested by the DIGAMI trial, may offer benefits in acute myocardial infarction but requires further confirmation.
- Revascularization strategies are debated, with drug-eluting stents showing promising results in reducing restenosis.
Conclusions:
- Diabetic patients with CAD require a comprehensive and aggressive management approach tailored to their specific needs.
- Optimizing glycemic control and utilizing evidence-based secondary prevention therapies are essential.
- Emerging evidence on insulin therapy and advanced stenting techniques offers hope for improved outcomes, pending further large-scale trials.
Abstract:
Type 2 diabetes has reached epidemic proportions and an increasing proportion of patients with coronary artery disease (CAD) are diabetics. CAD in diabetics has specificities and, in particular, more extensive atherosclerosis; diabetic patients are also more frequently asymptomatic, with silent myocardial ischemia, which makes the diagnosis of CAD more difficult. In addition, diabetic patients with CAD have poorer outcomes than nondiabetics. The management of diabetic patients with CAD is based on intensive intervention on lifestyle and risk factors, together with the mandatory use of medications of proven benefit as regards secondary prevention in coronary patients: antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors. Glycemic control is also essential; although the use of sulfonylureas has been controversial, there is now a vast amount of data suggesting a beneficial effect, in particular when agents more specific for the pancreatic adenosine triphosphate-dependent potassium (K(ATP)) channels are used. At the acute stage of myocardial infarction, the Diabetes mellitus, Insulin Glucose infusion in Acute Myocardial Infarction (DIGAMI) trial suggested a beneficial effect of insulin therapy prolonged for 3 months after hospital discharge; these data will have to be confirmed by larger intervention trials. Finally, the respective roles of coronary angioplasty and coronary surgery in diabetics are debated; a post hoc analysis of the Bypass Angioplasty Revascularization Investigation (BARI) trial data showed increased mortality in diabetics with multivessel CAD treated with angioplasty compared with surgery, but the results of the more recent trials using intracoronary stents appear more balanced; in this regard, the effects of drug-eluting stents, which dramatically decrease the incidence of re-stenosis, seem promising.